Source: Annual Congress 2008 - Current and future pulmonary arterial hypertension combination therapy
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Pepke-Zaba (Cambridge, United Kingdom). Targeting of PH by inhalative strategies. Annual Congress 2008 - Current and future pulmonary arterial hypertension combination therapy

Member's Comments

No comment yet.

Related content which might interest you: Specific immunotherapy added to pharmacologic treatment as a tool for working relocation in baker‘s occupational asthma Source: Annual Congress 2009 - High molecular sensitisers and biological dusts Year: 2009 Targeting small airways in asthma: the new challenge of inhaled corticosteroid treatment Source: Eur Respir J 2008; 31: 1145-1147 Year: 2008 Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension Source: Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019 Year: 2021 Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities Source: Eur Respir J 2014; 44: 513-522 Year: 2014 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies Year: 2009 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment Year: 2009 What the pulmonary specialist should know about the new inhalation therapies Source: Eur Respir J 2011; 37: 1308-1417 Year: 2011 Airway inflammation in asthma: current and future targets and therapies Source: Breathe 2010; 6: 245-252 Year: 2010 Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Novel and classical inhaled materials implicated in the causation of occupational airways diseases Source: International Congress 2019 – PG13 Traditional and modern clinical approaches for diagnosis and management of occupational airways diseases Year: 2019 Specificity of specific inhalation challenge with non-standard occupational agents in consecutive patients Source: International Congress 2017 – Asthma: clinical and epidemiologic characterisation Year: 2017 Targeting of drugs to the lung Source: Annual Congress 2003 - COPD vs AAT deficiency - similarities and differences Year: 2003 Single inhaler therapy with budesonide/formoterol in an allergic rat model: a new therapeutic strategy in asthma Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004 Oral presentation: Potential of ACE2 as a therapeutic target for pulmonary hypertension Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 Roles of α1-acid glycoprotein in therapeutic effects of imatinib in bleomycin-induced pulmonary fibrosis: benefits of macrolides Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair Year: 2007 Small airways targeting of inhaled steroids for severe therapy resistant asthma in children Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 Pharmacological characterization of CHF6162, a novel long acting inhaled corticosteroid for the treatment of asthma Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017